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Hereditary angio-oedema
Hilary Longhurst, Marco Cicardi
Hereditary angio-oedema is caused by a heterozygous deﬁ ciency of C1 inhibitor. This inhibitor regulates several 
inﬂ ammatory pathways, and patients with hereditary angio-oedema have intermittent cutaneous or mucosal swellings 
because of a failure to control local production of bradykinin. Swellings typically evolve in several hours and persist 
for a few days. In addition to orofacial angio-oedema, painless swellings aﬀ ect peripheries, which causes disﬁ gurement 
or interference with work and other activities of daily living. Angio-oedema aﬀ ecting the gastrointestinal tract or 
abdominal viscera causes severe pain often with vomiting due to oedematous bowel obstruction. About 2% of 
swellings involve the larynx and can be fatal if untreated. About 50% of patients have laryngeal swellings that are 
potentially fatal despite prophylaxis. In this Seminar we review the clinical features, diagnosis, and management of 
hereditary angio-oedema, with speciﬁ c emphasis on the new treatments available for acute swellings.
Introduction
The best known and more common form of hereditary 
angio-oedema is due to a genetic deﬁ ciency of C1 inhibitor; 
however, other forms of familial angio-oedema with 
normal concentrations of C1 inhibitor have been described 
in the past 10 years.1 Here we focus on hereditary angio-
oedema that is C1-inhibitor dependent. Patients with 
hereditary angio-oedema have episodic swellings that can 
aﬀ ect any part of the body. The absence of associated 
urticaria and the slow timecourse of swellings distinguish 
hereditary angio-oedema from allergic or anaphylactic 
angio-oedema. Asymmetric cutaneous swellings aﬀ ecting 
the hands, feet, face, or genitals, and swellings aﬀ ecting 
the gastrointestinal tract, are most common (ﬁ gure 1).2,3 
Intraoral swellings are rare but might progress to involve 
the larynx, and are of great concern to families aﬀ ected by 
hereditary angio-oedema, about 30% of whom have had a 
family death from obstruction of the upper airway. In a 
prospective study,2 46% of attacks were peripheral in 
location, 33% gastrointestinal, and 6% oral. 15% of 
patients had swellings occurring simultaneously at more 
than one location.2,4 Angio-oedema of the brain, joints, 
and abdominal viscera occur less often, and angio-oedema 
of the lower respiratory tract seems rare.5
Most episodes result in reversible disability lasting 
1–5 days. About 40–87% of swellings related to hereditary 
angio-oedema are preceded (by up to 16 h) by prodromal 
erythema marginatum, substantial fatigue, or local 
discomfort (ﬁ gure 1).6,7 Swellings accumulate within 
several hours. Peripheral swellings are usually moderately 
painless. Intra-abdominal swellings typically start with 
low-level discomfort, abdominal distension, and nausea 
for several hours, before entering a phase of exponential 
progression to very severe pain with vomiting or diarrhoea 
and, in severe cases, fainting due to hypovolaemia. During 
the phase of maximum pain, routine radiographs might 
show distended bowel loops, which is suggestive of 
obstruction, and ultrasonography might show ascites.8 
Capsule endoscopy can allow substantial oedema of the 
mucosa to be visualised (ﬁ gure 1; webvideo). Symptoms 
of hereditary angio-oedema are often mistaken for those 
of other acute abdominal disorders and many patients 
have a history of unnecessary surgery. Symptoms are at 
maximum intensity for up to 24 h before spontaneously 
resolving in a further day.9,10 Figure 2 represents a typical 
time course of abdominal symptoms.
The symptoms of intra-oral swelling might be mild and 
slowly progressive for several hours before entering a 
phase of rapid progression to asphyxiation.12 Patients who 
have had many non-obstructive laryngeal attacks, and 
physicians who are inexperienced in the management of 
hereditary angio-oedema, might not recognise the danger 
of intraoral swelling, which needs emergency treatment 
to arrest progression of the attack and sometimes a 
diﬃ  cult intubation or emergency tracheotomy. Patients 
occasionally report abdominal or laryngeal attacks that 
are rapidly progressive and precipitous, and time from 
onset to death can be as short as 20 min.12
At times of physical and psychological stress, during 
treatment with angiotensin-converting-enzyme (ACE) 
inhibitors or after pharmacological or physiological 
exposure to oestrogens, risk of attacks is increased.13–17 
ACE inhibitors do not directly precipitate attacks, but act 
by increasing baseline concentrations of local bradykinin.18 
The mechanism of intervention for the other triggering 
factors is unknown. Known precipitating factors do not 
inevitably result in swelling, but instead reduce the 
threshold for start of an attack. Despite the reversibility 
of the angio-oedema, its unpredictable nature and in 
particular its association with stressful situations results 
in diﬃ  culties for the patient, their family, and their 
employers that are proportionate to the severity of the 
disorder. Yearly costs per patient in the USA that were 
Search strategy and selection criteria
We searched PubMed from 1948, to June, 2011, the Cochrane 
database, clinical trials.gov, and Embase using the terms 
“hereditary angio-oedema”, “hereditary angioedema”, 
“C1 inhibitor”, and “C1 esterase inhibitor” alone, and in 
combination with the terms “clinical trial”, “meta-analysis”, 
“practice guideline”, and “randomised controlled trial”. 
Full-text articles were retrieved for the most relevant articles. 
We did not have any exclusion criteria, although abstracts of 
papers that seemed irrelevant were not retrieved.
See Online for webvideo
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calculated before the availability of deﬁ nitive acute 
treatment were about US$42 000 overall, and $92 000 for 
severe disease.19 Studies of angio-oedema do not 
necessarily account for the substantial and widespread 
costs of lost opportunity, or for the indirect costs to the 
family, the employer, or to society.
Epidemiology
Surveys of patients suggest that hereditary angio-oedema 
aﬀ ects about 1 in 50–100 000 of any ethnic group, with 
many of those aﬀ ected being unaware of their diagnosis.6,20 
Although the deﬁ ciency is lifelong, swellings rarely occur 
before the age of 2 years and are less frequent before 
adolescence. Mean age at onset of symptoms is about 
8–12 years.21 Incidence of swellings varies from more than 
one swelling per week to less than one per year.2 In a 
random sample of 103 patients with hereditary angio-
oedema, with and without long-term prophylactic 
treatment, the mean frequency of angio-oedema was once 
every 45·3 days.4 Large diﬀ erences in disease severity have 
even been noted within families, who naturally have the 
same mutation in C1 inhibitor. Polymorphisms away from 
the C1-inhibitor gene (particularly those aﬀ ecting the 
contact system), environmental factors (such as emotional 
stress, exposure to infections, inﬂ ammatory stimuli), or 
low-level trauma, and variations in concentrations of sex 
hormones might all play a part in determining the 
frequency and severity of swellings.2,13–17,22
Pathogenesis and regulation of inﬂ ammatory 
pathways
C1 inhibitor belongs to the protein family of serine 
protease inhibitors and, as with other members of this 
family, functions with a suicide mechanism that has been 
compared to a mouse trap.23 When the C1-inhibitor lands 
on its target protease, it is cleaved and the carboxyl-
terminal end of the cleavage site—arginine 444—covalently 
binds the protease. The protease-binding part of the 
inhibitor is then rotated and inserted into its globular part 
to keep the protease in an inactive state.24,25 Mutations 
altering the aminoacid sequence of the inhibitor almost 
invariably result in its deﬁ ciency. More than 200 diﬀ erent 
mutations have been described in families with hereditary 
angio-oedema. Less than 20% of these mutations are large 
insertions or deletions, the rest are missense, frameshift, 
splicing defects, or nonsense defects due to changes in 
one or several bases.26 Mutations in the C1-inhibitor gene 
can either prevent synthesis of a protein product that is 
detectable in plasma resulting in hereditary angio-oedema 
type 1, or can allow the synthesis of a protein product with 
impaired function resulting in hereditary angio-oedema 
type 2. Mutations causing the type 2 disorder are located 
mostly on exon 8 and aﬀ ect the nucleotides coding for the 
aminoacids that form the reactive site of the protein.27
C1 inhibitor acts as a regulator of several inﬂ ammatory 
pathways (ﬁ gure 3). In the classic complement pathway, 
C1 inhibitor is the only inhibitor of the C1r and C1s 
complement components in the classical pathway, and 
inhibits mannan-binding lectin-associated serine 
protease 2 in the lectin pathway. Both pathways converge 
to activate complement components C4 and C2. Deﬁ ciency 
in C1-inhibitor results in chronic overactivation and 
consumption of these components, which are substantially 
reduced in the plasma of patients with hereditary angio-
oedema. Overactivation of the classical and lectin path-
ways does not progress to the common pathway and C3 
concentration is typically normal, probably because 
reactions occur in the ﬂ uid phase.28 Abnormalities in the 
Figure 1: Clinical manifestations of hereditary angio-oedema
(A) Angio-oedema of hand in patient with hereditary angio-oedema. (B) Capsule endoscopy during abdominal attack in patient with hereditary angio-oedema,
showing ileal tract with normal mucosa and lumen (left), and oedematous ileum and substantially reduced luminal diameter, causing partial bowel obstruction 
(right). (C) Erythema marginatum on anterior chest wall of patient with hereditary angio-oedema 8 h before onset of abdominal symptoms.
Figure 2: Pain intensity experienced during severe abdominal attack of 
hereditary angio-oedema9–11
How early treatment can reduce pain and duration of attack. Continuous line 
shows time course of untreated attack. Dotted lines show time course of attacks 
treated with C1-inhibitor replacement early or late in course of attack.
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complement pathway are important in diagnosis, but are 
probably not responsible for swellings.
A second pathway is the contact pathway in which 
C1 inhibitor regulates coagulation factor XII (Hageman 
factor) and kallikrein, which controls production of 
bradykinin and leads to angio-oedema in patients who are 
C1-inhibitor deﬁ cient.29 Bradykinin is a potent local 
vasodilator that has a paracrine mode of action that 
activates adjacent G-protein-coupled receptors of the 
bradykinin type-2 receptor that are constitutively expressed 
on many cells. Another type of speciﬁ c receptor, bradykinin 
type-1, which is expressed after inﬂ ammatory stimuli, has 
also been described. Although the physiological role of the 
type-1 receptor is unclear, it might also have a role in the 
pathogenesis of symptoms of hereditary angio-oedema.30 
Bradykinin is the main mediator of angio-oedema in 
hereditary angio-oedema. In patients with the disorder, 
baseline concentrations of systemic bradykinin are 
increased. Concentrations further increase in episodes of 
angio-oedema and are much higher when blood is 
obtained from a swollen limb than when it is 
simultaneously obtained from the unaﬀ ected limb.31–33 
One family with a C1-inhibitor gene mutation aﬀ ecting 
complement regulation, but with preserved kallikrein 
inhibitory activity, did not have angio-oedema; however, 
they did present with systemic lupus erythematosus (SLE) 
because of the acquired deﬁ ciency in C2 and C4.34
Clotting and ﬁ brinolytic pathways are a third type of 
pathway regulated by C1 inhibitor. The actions of 
C1 inhibitor on clotting factors XI and thrombin, and its 
inhibition of plasmin and tissue-type plasminogen 
activator, do not result in phenotypic abnormalities, but do 
inﬂ uence angio-oedema pathogenesis.35 Other actions of 
C1-inhibitor include its binding to several extracellular 
matrix components, to complement component C3b in a 
way that is analagous to factor H, with E- and P-selectins 
on endothelial cells, and directly to endotoxin.36 This 
binding seems to be independent of the protease activity of 
C1 inhibitor. Although the relevance of these interactions 
to patients with hereditary angio-oedema is unclear, they 
might be relevant to future therapeutic uses for C1 inhibitor. 
The various anti-inﬂ ammatory eﬀ ects of C1 inhibitor have 
shown promise in non-human testing in other indications, 
such as stroke, multiple trauma, and graft rejection.37,38
Diagnosis
Patients with hereditary angio-oedema typically have a 
mean delay of more than 10 years between onset of 
symptoms and diagnosis.20 This delay is important 
because conventional treatments, such as corticosteroids 
and antihistamines, are unlikely to be eﬀ ective, and 
because most deaths occur in those who are 
undiagnosed.2,39 Deﬁ ciency of the C4 complement 
component, and normal concentration of C3, is typical of 
hereditary angio-oedema, even in asymptomatic patients, 
and has been recommended as a screening test.40 
However, C4 concentration is occasionally normal even 
in untreated patients,41 and deﬁ nitive diagnosis requires 
measurements of C1 inhibitor. 85% of patients have low 
concentrations of C1-inhibitor protein (hereditary angio-
oedema type 1), and 15% have normal or high 
concentrations of a non-functional C1-inhibitor protein 
(type 2). Functional measurements of C1 inhibitor are 
needed for patients with the type-2 disorder.42
C1-inhibitor function is usually measured in reference 
laboratories with two methods: a chromogenic assay that 
detects the capacity of C1 inhibitor in patients’ serum to 
inhibit the ability of C1s to aﬀ ect a colour change in a 
chromogenic substrate; and an ELISA that measures the 
ability of C1 inhibitor in patients’ serum to bind to 
exogenous biotinylated C1s. Both assays function well in 
optimum conditions, but refrigeration or delay in 
samples being processed results in functional 
measurements that are artifactually low, particularly for 
the chromogenic assay.43 ELISA works diﬀ erently from 
the more commonly used chromogenic assay, and results 
are not directly comparable. Local determination of 
normal ranges might result in a higher cutoﬀ  with the 
ELISA than is recommended by the manufacturer.41,43 
Routine blood tests, such as blood count, creatinine, 
electrolytes, and C-reactive protein, are unaﬀ ected by 
deﬁ ciencies in C1 inhibitor.
Figure 3: Serine proteases controlled by C1 inhibitor in pro-inﬂ ammatory cascade systems
Red crosses indicate inhibition by C1-INH. (A) C1 inhibitor blocks activated C1r, C1s, and MASP2 in complement 
system, which prevents excessive proteolysis of C4 and C2 components. (B) In coagulation system, C1 inhibitor blocks 
activated FXIIa and FXIa preventing thrombin formation through activation of FIXa and FXa. In ﬁ brinolytic system C1 
inhibitor might have a role in preventing formation of plasmin by inhibition of t-PA and FXIIa, and also prevents 
formation of FDP by inhibition of plasmin. (C) In contact-kinin system, through inhibition of FXIIa and active plasma 
kallikrein, C1 inhibitor controls positive ampliﬁ cation loop of activation of these two enzymes, thus preventing release 
of bradykinin by internal cleavage of HMWK. (D) Deﬁ ciency of C1 inhibitor allows excessive formation of plasma 
kallikrein and FXIIa, which are bound in complex with HMWK to speciﬁ c receptors CK-1, gC1qR, and uPAR on 
endothelial cells. (E) Uninhibited active plasma kallikrein releases bradykinin that acts as paracrine hormone, 
stimulating speciﬁ c G-protein coupled BK2-Rs that increase capillary permeability allowing oedema formation. 
MASP2=mannan-binding lectin serine protease 2. t-PA=tissue plasminogen activator. FXIIa=coagulation factor XII. 
FXIa=coagulation factor XI. FIXa=coagulation factor IX. FXa=coagulation factor Xa. FDP=ﬁ brinogen degradation 
products. C1-INH=C1 inhibitor. HMWK=high-molecular-weight kininogen. BK2-R=bradykinin type-2 receptor. 
CK-1=cytokeratin 1. uPAR=urokinase plasminogen activator receptor. gC1qR =globular head of C1q receptor.
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Diﬀ erential diagnosis
Clinical and laboratory ﬁ ndings should be considered 
when hereditary angio-oedema is diagnosed (panel), with 
one study suggesting that up to 25% of patients had a 
doubtful diagnosis.44 C4 concentrations might be reduced 
in SLE, hypocomplementaemic urticarial vasculitis, 
cryoglobulinaemia, or cytokine-release syndromes. In 
these situations, C1 inhibitor will be consumed, but rarely 
to the extent of measurable deﬁ ciency. Thus normal 
concentrations of C4 in an untreated patient, or C4 
deﬁ ciency with atypical clinical features that are suggestive 
of inﬂ ammatory disorders, should alert the clinician to 
the possibility of sample deterioration causing artifactually 
reduced function of C1 inhibitor.
SLE-like syndromes occasionally complicate hereditary 
angio-oedema, and secondary C1-inhibitor deﬁ ciency 
(acquired angio-oedema) might complicate lympho-
proliferative or autoimmune disorders, including SLE.45,46 
By contrast with hereditary angio-oedema, symptoms of 
acquired C1-inhibitor deﬁ ciency start at an older age and 
there is no family history. Features of lymphoproliferative 
disease, or, most typically, an asymptomatic monoclonal 
gammopathy of unknown signiﬁ cance are sometimes 
present.47 C1q concentrations are normal in hereditary 
angio-oedema but are often reduced in acquired 
C1-inhibitor deﬁ ciency; measurements might be helpful 
when secondary deﬁ ciency is suspected.47 Although genetic 
diagnosis is not normally needed, it might be helpful to 
resolve diagnostic doubt or for children aged less than 1 year 
in whom plasma and serum testing can be unreliable.48
Angio-oedema with no urticaria that does not respond to 
antihistamines is typical of bradykinin-mediated angio-
oedema. Other presumed bradykinin-mediated angio-
oedemas, such as hereditary angio-oedema type 3 
(associated with mutations in coagulation factor XII), 
hereditary angio-oedema induced by angiotensin-
converting-enzyme inhibitor, and some idiopathic angio-
oedemas might mimic hereditary angio-oedema. However, 
unlike in hereditary angio-oedema, swellings in bradykinin-
mediated angio-oedemas mostly aﬀ ect the face, mouth, 
and larynx, and there is no abnormality in the complement 
pathway or in C1 inhibitor.49,50 The accurate diﬀ erentiation 
of bradykin-mediated angio-oedema from histamine-
mediated angio-oedema and from hereditary angio-
oedema will be important for fu ture treatment options. 
Figure 4 is a suggested algorithm for diagnosis of hereditary 
angio-oedema. By contrast with diagnostic testing, which 
despite the pitfalls is usually straightforward, no routinely 
available tests are available to diagnose acute attacks in 
patients with known hereditary angio-oedema and atypical 
symptoms,52 and such tests are urgently needed. Treatment 
of attacks is costly but most eﬀ ective if given early in the 
attack when symptoms and signs are non-speciﬁ c.
Management and prophylaxis
Almost every patient with C1-inhibitor deﬁ ciency will 
have episodes of angio-oedema during their lifetime with 
substantial morbidity and mortality.2 The ﬁ rst episode 
can be (but is rarely) fatal;12 therefore, every patient needs 
a plan for treatment of acute attacks, irrespective of the 
severity or frequency of symptoms. For those with 
frequent or disabling attacks occurring more than once a 
month, long-term prophylaxis should also be 
considered.53,54 17-α-alkylated attenuated androgens, such 
as danazol, stanozolol, oxandrolone, and tibolone, and 
(unattenuated) methyl-testosterone, reduce the frequency 
and severity of attacks in most patients.55,56 International 
consensus now recommends reduced doses—ie, a 
maximum of 200 mg danazol or 2 mg stanozolol daily.57 
High doses increase the risk of side-eﬀ ects. Historically, 
side-eﬀ ects are common and relate either to the residual 
androgenic properties of the drug, or to the 17-α-side-
chain.57,58 Regular liver function, cholesterol, and blood-
pressure monitoring, and biannual liver ultrasonography 
to exclude hepatic adenoma, are speciﬁ cally recommended 
for patients who need these drugs long-term.57,60 
Fibrinolytics, such as tranexamic acid or aminocaproic 
acid, are also used as prophylactics either continuously 
or at the early stages of mild attacks.61,62 Fibrinolytics are 
of partial beneﬁ t at best, and not eﬀ ective in severe or 
established attacks.63,64 They are used for children in 
preference to androgens, which might aﬀ ect growth.
The C1-inhibitor replacement, cinryze, has been 
licensed for prophylaxis in the USA on the basis of a 
double-blind crossover study of patients who had frequent 
attacks (more than two per month).65,66 Patients were 
assigned to 12 weeks of 1000 units of C1-inhibitor twice 
weekly, or placebo for 12 weeks, before crossing over to 
the other group. C1-inhibitor prophylaxis was strongly 
associated with fewer swellings that were reduced in 
severity, shorter duration of attacks, a lower total number 
of days of swelling, and fewer on-demand C1-inhibitor 
Panel: Criteria for diagnosis of hereditary angio-oedema
Diagnosis is obtained with one clinical and one laboratory criterion. When clinical criterion 
is family history, the individual is an asymptomatic carrier of hereditary angio-oedema.
Clinical criteria
• Recurrent subcutaneous angio-oedema that is non-pitting, non-pruritic, 
non-erythematous, and self limiting, and usually lasts for more than 12 h with no 
major urticaria
• Unexplained, recurrent abdominal pain (often accompanied by vomiting and 
diarrhoea), which spontaneously resolves in 24–72 h
• Recurrent oral, pharyngeal, or laryngeal oedema
• Documented family history of hereditary angio-oedema
Laboratory criteria
• Antigenic concentrations of C1 inhibitor <50% of normal values obtained on two 
separate occasions after ﬁ rst year of age
• Functional levels of C1 inhibitor <50% (chromogenic assay) or <84% (ELISA assay; 
local normal ranges might vary) of normal values obtained on two separate occasions 
after ﬁ rst year of age39,41
• Mutation in C1-inhibitor gene that modiﬁ es protein synthesis or function
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treatments. However, this prophylaxis did not completely 
abolish attacks for everyone, and two of 22 patients had 
more frequent swellings when in the active treatment 
group than when on placebo.65,66 Thus, as with other 
forms of prophylaxis, C1 inhibitor seems to raise the 
threshold for swellings but might not completely abolish 
them; however, variations in the frequency or dose 
according to individual needs could improve control. 
Because androgens are contraindicated during pregnancy, 
although unlicensed, C1-inhibitor prophylaxis is 
particularly useful when prophylaxis is needed.
Prophylaxis can be used during periods of high-risk for a 
swelling. Traditional indications for short-term prophylaxis 
include surgical procedures, particularly dental work. Local 
trauma increases the risk of swellings, which typically 
occur 4–48 h after surgery.13,67 Swellings usually occur in 
the area of trauma; therefore, dental work is of particular 
concern because of the risk of intra-oral swelling extending 
to involve the larynx. Consensus guidelines recommend 
use of C1-inhibitor concentrate before the procedure or, if 
this is unavailable, the dose of attenuated androgen should 
be doubled for 5 days before and 2 days after the procedure, 
which can reduce the risk of swelling; however, eﬃ  cacy 
data are scarce.57,58 Fresh frozen plasma contains 
C1 inhibitor, and case reports suggest that 2–3 units of this 
plasma might be an alternative when C1 inhibitor is not 
available.68 In practice, decisions about prophylaxis will be 
made pragmatically dependent on the site and invasiveness 
of the procedure and on the frequency and severity of 
symptoms that the patient usually experiences. Whatever 
the decision, there is an increased risk of swelling and 
there should be a plan for emergency treatment. Because 
of the slow onset of surgically induced swellings, hereditary 
angio-oedema is not a contraindication for community or 
day-case treatment, nor should emergency procedures be 
delayed if prophylaxis is not immediately available. Other 
indications for short-term prophylaxis, usually with 
attenuated androgens, would be during high-risk periods 
due to emotional stress, such as interviews, exams, or 
celebrations, or when swellings would be particularly 
inconvenient, such as holidays. Treatment of prodromal 
symptoms with C1-inhibitor concentrate is also eﬀ ective 
and might need lower doses than those needed for a fully 
developed attack. In practice, this treatment is feasible only 
for those who are trained in self-administration.11
Treatment
Options for treatment of established swellings have 
increased in the past few years and include replacement 
of C1-inhibitor with plasma-derived products (ie, cinryze 
or berinert P), bradykinin receptor and kallikrein 
antagonists, and a recombinant C1 inhibitor. All 
treatments are eﬀ ective for swellings at any site. After 
treatment, most patients take 15–120 min before onset of 
relief, and major swellings might take up to 24 h to 
completely resolve.10,65,66,69–78 Swellings respond more 
quickly when treated early in the course of the attack.10 
However, treatment is costly, and a balance should be 
made between early treatment of an attack that might 
never become severe, and late treatment resulting in a 
substantially increased period of disability.
Plasma-derived C1 inhibitor has been used for more 
than 25 years and has been eﬀ ective in double-blind 
placebo-controlled trials.65,72,76,77 A dose-ﬁ nding trial—which 
was limited by small size and use of only 3 tested doses of 
C1 inhibitor—indicated that doses of 20 units per kg are 
substantially more eﬀ ective than placebo, whereas the 
traditional dose of 10 units per kg is not.72 Increased doses 
have not been tested for plasma-derived C1 inhibitor, but 
doses of up to 50–100 units per kg have been investigated 
with ruconest. These studies suggest that most patients 
respond to doses of 50 units per kg or more.75,78,79 However, 
ruconest cannot be directly compared with plasma-derived 
C1 inhibitors for which dose-ﬁ nding studies are needed. 
In fact, observational studies suggest that low doses of 
C1 inhibitor—1000 or even 500 units—might be eﬀ ective 
in some cases. Small swellings or very early symptoms 
might be eﬀ ectively treated with low doses, which is 
usually achievable only in the context of self-administration 
or other rapid-access programmes. A ﬁ rst dose, with a 
second one if symptoms persist, has been tested;66 
however, the population that used single or repeated dose 
has been analysed only cumulatively and therefore the 
speciﬁ c advantage or disadvantage of this approach cannot 
be determined. Ruconest is harvested from the milk of 
genetically modiﬁ ed rabbits, and although its protein 
structure is identical to that of plasma-derived C1 inhibitor, 
it has diﬀ erent glycosylation. This diﬀ erence does not 
seem to aﬀ ect the biological activity of ruconest, but does 
result in a much reduced half-life of mean 3 h compared 
with 24 h or more for plasma-derived C1 inhibitors.75,80 
Figure 4: Algorithm for diagnosis of angio-oedema due to C1-inhibitor 
deﬁ ciency
Angio-oedema occurs in absence of relevant urticaria ﬂ are and without 
cause-eﬀ ect correlation with exposure to speciﬁ c food or drug. In cases of doubt, 
to rule out histamine-mediated angio-oedema, patients should have 
continuous treatment with anti-H1-histamine receptor at a daily dose that is 
2–3 times more than that recommended for allergic rhinitis. If angio-oedema 
recurs with this treatment regimen, and onset of angio-oedema did not occur 
while patient was treated with ACE-inhibitor, bradykinin-mediated 
angio-oedema is probable and biochemical tests for C1 inhibitor deﬁ ciency 
should be repeated, with genotyping if available. Adapted from reference 51.
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Drug-related adverse reactions and development of 
clinically important antibodies have not been seen in 
trials, even after repeated administration. However, in a 
phase 1 studiy,74 a healthy volunteer with severe rabbit 
allergy and high concentrations of rabbit-speciﬁ c IgE had 
an anaphylactic reaction after intravenous ruconest.
Icatibant acetate, a subcutaneous synthetic peptide 
blocker of the bradykinin-2 receptor, has been assessed in 
two double-blind trials;63 one in the EU and Israel against 
tranexamic acid, the other in America (ie, North and 
South America [USA, Brazil, Argentina]) against placebo. 
In a comparison with tranexamic acid, subcuta neous 
icatibant acetate provided faster onset of relief and time to 
full resolution for swellings at all sites. Whereas in a 
comparison with placebo, icatibant acetate was eﬀ ective 
for the treatment of peripheral swellings, but not for 
abdominal pain. These ﬁ ndings probably indicate an 
underpowered trial with subjective outcome measures 
(visual analogue scores), and failure to censor patients 
who received nonspeciﬁ c treatments, such as narcotic 
painkillers or intravenous rehydration, which would be 
expected to improve pain scores. Both trials showed a 
higher use of adjunctive and rescue treatments in the 
placebo or tranexamic acid group than in the icatibant 
group. Icatibant has been tested in animals and human 
beings for various indications and seems to have few 
systemic side-eﬀ ects; the incidence of systemic adverse 
eﬀ ects in the trials was similar between the icatibant 
group and the placebo or tranexamic acid group. Local 
erythema and pain at the injection site is almost universal 
with icatibant. About 10% of those treated with icatibant 
have recurrent swellings after 16–24 h, which are usually 
at the same site.64,70 Although recurrent swellings are 
usually slow in onset, swellings occasionally develop 
rapidly. A second injection of icatibant or C1-inhibitor 
treatment is eﬀ ective.64,72
Ecallantide, a small recombinant protein kallikrein 
antagonist that is synthesised in Pichia pastoris, has been 
licensed in the USA for the treatment of acute hereditary 
angio-oedema. In three double-blind placebo-controlled 
studies,81–83 ecallantide was better than placebo in 
improving symptoms measured by one of two composite 
measurements—treatment outcome score and mean 
symptom-complex score—which were designed to 
indicate overall severity of disease symptoms. The 
subcutaneous formulation of ecallantide improves 
convenience. However, administration outside a health-
care facility is not recommended: of 187 patients given to 
subcutaneous ecallantide (the marketed form) 4% had 
hypersensitivity events, including anaphylaxis in 2%.84 
8% of participants developed antibodies to either 
P pastoris or ecallantide itself, of which 2% seemed to be 
neutralising. However, neither the occurrence of 
reactions nor eﬀ ectiveness correlated with the presence, 
class, or neutralising ability of antibodies. Nine patients 
who had reactions underwent desensitisation, and four 
were then rechallenged with no adverse eﬀ ects.85
Self-administration programmes have been helpful in 
enabling early access to treatment, and are recom-
mended by consensus guidelines.57,58,86–89 However, such 
programmes have been limited to the small proportion 
of patients willing to have intravenous administration of 
C1 inhibitor. Icatibant was licensed in Europe in 2008, 
for administration by health-care professionals, and was 
licensed for self-administration in 2011.90 Icatibant’s 
subcutaneous route of administration might enable an 
increased number of patients to control their own acute 
attacks; therefore, the need for emergency health-care 
facilities will potentially be reduced, as will the 
disadvantage incurred by the unpredictable episodic 
disablement that attacks bring.
Future directions
Progress in the management of acute attacks has been 
rapid, and several eﬀ ective drugs are now available. These 
drugs will enable early treatment of attacks, which will 
prevent the development of disabling symptoms and 
improvements in quality of life. Self-administration 
programmes will reduce patients’ reliance on acute 
hospital services. More information about optimum 
dose, pharmacokinetics, and feasibility of subcutaneous 
treatment with C1 inhibitor, and about how use of 
icatibant and ecallantide can be best timed, will enable 
improved use of resources.
Safe, convenient, and eﬀ ective prophylactic drugs are 
needed, and although none are in trials, gene therapy is a 
possibility. Alternatively, oral acute drugs could reduce 
the need for prophylaxis. Because early treatment would 
be best in view of non-speciﬁ c symptoms, sensitive and 
speciﬁ c methods for diagnosis to conﬁ rm an early attack 
are needed. Quality of life and pharmacoeconomic data 
are needed to support possible increases in future 
demand for treatment.
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